[Asia Economy Reporter Jang Hyowon] THE E&M subsidiary LUCA AICell has completed preparations to expand its bio business involving Supported Lipid Bilayer (artificial cell membranes).
On the 30th, THE E&M announced that its subsidiary LUCA AICell signed a facility contract to establish its headquarters within Pyeongchon Smart Square in Anyang-si, Gyeonggi-do, in order to obtain KGMP certification for medical devices, which is an essential requirement for pharmaceutical manufacturing and sales quality management.
On the 10th, THE E&M established LUCA AICell as a subsidiary to enter the new bio business related to artificial cell membranes. LUCA AICell appointed Dr. Namjun Cho, a world-renowned scholar and expert in artificial cell membranes who developed new drug technology to effectively treat hepatitis C infections, as its new CEO.
Based on various global patented technologies including artificial cell membranes owned by Dr. Namjun Cho, LUCA AICell plans to promote businesses such as virus and cancer diagnostics, medical device coatings, new drug development, and drug testing platforms.
Dr. Namjun Cho, CEO of LUCA AICell, stated, “Virus and cancer diagnostics using artificial cell membranes mark the beginning of proactive and aggressive solutions to fatal threats that could harm human health in the future.”
Meanwhile, on the 23rd, THE E&M granted stock options to Dr. Namjun Cho as a growth incentive and to encourage performance, aiming for mutual growth with LUCA AICell.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
